3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Completed
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Gynecologic
9
Gastrointestinal
5
Thoracic
4
Breast
4
Genitourinary
3
Dermatologic
3
Head & Neck
2
CNS
2
Tumor-Agnostic
1
Sarcoma
1
Plasma cell
1
Other hematologic neoplasm
1
Lymphoid
1
Conditions
Waldenstrom Macroglobulinemia
1
Multiple Myeloma
1
Influenza, Human
1
Interventions
Dexamethasone
393
Bortezomib
246
Lenalidomide
222
Cyclophosphamide
184
Melphalan
168
Calcium Dobesilate
119
Peripheral Blood Stem Cell Transplantation
94
fludarabine phosphate
89
Thalidomide
82
Filgrastim
74
carfilzomib
70
pomalidomide
68
Granulocyte Colony-Stimulating Factor
63
Busulfan
63
Mycophenolic Acid
61
daratumumab
58
Whole-Body Irradiation
57
ixazomib
54
fludarabine
52
Tacrolimus
52
Prednisone
51
Cyclosporine
50
Antilymphocyte Serum
35
dexamethasone acetate
32
plerixafor
30
Etoposide
30
Methotrexate
29
Radiotherapy
28
dexamethasone 21-phosphate
27
Doxorubicin
26
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Completed
×
Vaccines
×
Plasma cell
×
Clear all
NCT02566265
2019-01-30
SHIVERING 2
Yale University
Phase 2
Completed
122 enrolled
10 charts